3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Cholangiocarcinoma
10
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma
2
Sarcoma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Locally Advanced Unresectable Gastric Cancer
1
Gastrointestinal Stromal Tumors
1
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Acrocephalosyndactylia
1
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
pemigatinib
×
Gastrointestinal
×
Clear all
NCT07434843
2026-05-22
PEMIGIST
Dana-Farber Cancer Institute
Phase 2
Recruiting
24 enrolled